ADC Payload Summit

The ADC payload landscape is shifting rapidly. Driven by clinical successes of lower potency topoisomerase I inhibitors and as payloads that elicit novel modes of action continue to gain momentum, ADC developers are looking to harness these payload technologies to diversify the mechanism of action, widen the therapeutic index and expand the disease indications that ADCs can see a benefit in. As part of the World ADC Series, the ADC Payload Summit will deep dive into how you can alter the chemistry of well-explored payloads to see an enhanced therapeutic effect, explore novel cytotoxic payloads that provide a new way to kill cancer cells and evaluate the challenges and opportunities that lower potency and non-oncology payloads offer. This unique forum will equip you with the know-how to make the biggest impact on your ADCs efficacy through your payload R&D. As the first and only conference exclusively focusing on ADC Payloads, this is your opportunity to join 60+ of your peers working in Chemistry, Medicinal Chemistry and Discovery to uncover how using structure-activity relationship studies can optimize traditional topoisomerase I inhibitors, tubulin inhibitors and DNA damaging agents, explore novel mechanisms of action from oligonucleotide, degrader, RNA polymerase and NMT payloads, and understand how payload choice impacts linker and conjugation strategies.

Event Links

Website: https://go.evvnt.com/2225021-0

Tickets: https://go.evvnt.com/2225021-2

Brochure: https://go.evvnt.com/2225021-3

Read More

View Less